Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael McClung

Endocrinology, Diabetes & Metabolism Portland, OR Medical Doctor

NPI 1477580207 CMS profile 202949

5050 Ne Hoyt St, Suite 651, Portland, OR 97213

Open in the dashboard

General payments

$1,300,684

1,414 records reported · program years 2019–2025

Research payments

$28,911

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$25,185 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Michael McClung of Portland, OR is reported in the CMS Open Payments database as having received $1,300,684 across 1,414 general payments and $28,911 in research payments paid to them. Separately, studies naming them as principal investigator received $25,185 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,799 155
2024 General $262,702 298
2024 Research $15,072 2
2023 General $188,653 271
2022 General $120,058 154
2022 Research $3,500 1
2021 General $108,629 61
2021 Research $3,689 3
2020 General $112,314 109
2020 Research $4,200 4
2019 General $360,528 366
2019 Research $2,450 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael McClung
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michael McClung were reported at $147,799. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michael McClung Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $360,528 $494 $123–$2,253 $163
2020 $112,314 $335 $85–$1,841 $114
2021 $108,629 $398 $88–$1,981 $132
2022 $120,058 $364 $88–$1,568 $149
2023 $188,653 $420 $113–$1,614 $160
2024 $262,702 $440 $121–$1,646 $164
2025 $147,799 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,240,763 1,326 payments
  2. Alexion Pharmaceuticals, Inc. $21,051 31 payments
  3. Kyowa Kirin, Inc. $9,237 16 payments
  4. Ucb SA $8,008 5 payments
  5. Novo Nordisk Inc $6,000 2 payments
  6. Pfizer Inc. $4,621 3 payments
  7. Radius Health, Inc. $3,962 11 payments
  8. AbbVie, Inc. $2,724 7 payments
  9. Sumitomo Pharma America, Inc. $2,085 2 payments
  10. Myovant Sciences Inc. $646 2 payments
  11. Other $1,586 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $806,725 293 payments
  2. Consulting Fee $318,286 87 payments
  3. Travel and Lodging $147,971 715 payments
  4. Food and Beverage $23,911 317 payments
  5. Honoraria $3,791 2 payments
Products named General payments · program years 2019–2025
  1. EVENITY Bone Health $805,536 822 payments
  2. Prolia $444,450 456 payments
  3. Crysvita $9,073 14 payments
  4. Repatha Cardiology $4,569 2 payments
  5. Tymlos $3,675 5 payments
  6. XGEVA $3,000 2 payments
  7. REPATHA Cardiovascular $1,313 3 payments
  8. Evenity Bone $1,250 1 payment
  9. STRENSIQ Rare Disease $834 3 payments
  10. Strensiq Endocrinology $700 1 payment
  11. Other $1,825 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Amgen Inc. $18,761 4 payments
  2. E.R. Squibb & Sons, L.L.C. $10,150 8 payments

Records

1,426 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record